Uses of medication: Cobimetinib is a kinase inhibitor used for the treatment of patients with unresectable/metastatic melanoma with a BRAF V600E or V600K mutation, together with the vemurafenib (Zelboraf).
Dosage: Take cobimetinib tablets exactly as your healthcare practitioner tells you. The recommended cobimetinib dose is 60 mg (three 20 mg tablets), which should be taken orally, either with or without food, once daily for the initial 21 days (3 week) of each 28-day cycle until the time of disease progression or unacceptable toxicity.
Treatment Reactions: The most commonly reported cobimetinib side effects may include:
- Photosensitivity reaction
Apart from this, the most common grade 3-4 laboratory abnormalities are as:
- Increased GGT
- Increased CP
- Increased ALT
- Increased AST
- Increased alkaline phosphatase
Warnings and precautions
- Avoid sunlight while on the treatment with cotellic 20 mg. This medication may be responsible for making your skin sensitive to the sunlight. You may burn a quite easily and get severe sunburns.
- Monitor patients taking cobimetinib, when used together with vemurafenib, for signs/symptoms of non-cutaneous malignancies.
- Serum creatinine should be measured prior to initiation of vemurafenib and periodically during treatment.
- Cotellic can be responsible for causing fetal harm when given to a pregnant woman. Instruct females of reproductive potential to use effective contraception while on treatment and for 2 weeks following the final cotellic dose.
- Advise women not to breastfeed during treatment with cobimetinib 20 mg tablet and for 2 weeks following the final dose.
- Patients should be instructed to contact their healthcare practitioner in order to seek immediate medical attention for signs/symptoms of the unusual severe bleeding/hemorrhage.
- Liver laboratory tests should be monitored prior to initiation of the vemurafenib cobimetinib and monthly while on treatment, or quite frequently as clinically indicated.
- Dermatologic monitoring should be conducted for the 6 months following discontinuation of the cobimetinib fumarate when used together with the vemurafenib.